Cell & Gene Therapy 2021

A new platform for generating monoclonal cell lines for gene therapies with double assurance of clonality

Wed19  May03:05pm(5 mins)
Conference Hall
Dr Elly Sinkala


There is increasing pressure for high-throughput development and production of cell and gene therapies as many are progressing through clinical trials for eventual patient use. To ensure high quality of gene therapies from cell lines such as HEK293, which is often used to produce AAV and lentiviral vectors, it is important to prove that the resulting products were derived from a clonal cell line. This is often a bottleneck, however for the first time a single instrument provides a solution to this challenge. The UP.SIGHT combines single-cell cloning with a new imaging technology for 3D full well imaging to generate cell lines for gene therapies with probability of monoclonality of >99.99%. This workflow can reduce the time required to determine high titer clones and improve the overall process of gene therapy development.
To view the video assoicated with this lecture click here

Hosted By


The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis